Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Conditions

• Stage III Non-small Cell Lung Cancer

Interventions

• DRUG: Durvalumab
• DRUG: nanoparticle albumin bound paclitaxel
• RADIATION: low dose radiation therapy

Sponsor

Juan LI, MD